Compare OGN & RVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | RVLV |
|---|---|---|
| Founded | 1923 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2020 | 2018 |
| Metric | OGN | RVLV |
|---|---|---|
| Price | $13.51 | $25.96 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $11.40 | ★ $29.73 |
| AVG Volume (30 Days) | ★ 2.4M | 802.9K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ 24.64 |
| EPS | ★ 0.55 | 0.20 |
| Revenue | ★ $6,216,000,000.00 | $1,225,682,000.00 |
| Revenue This Year | $0.45 | $10.96 |
| Revenue Next Year | $1.67 | $8.01 |
| P/E Ratio | ★ $24.59 | $124.55 |
| Revenue Growth | N/A | ★ 8.48 |
| 52 Week Low | $5.69 | $17.35 |
| 52 Week High | $13.60 | $31.68 |
| Indicator | OGN | RVLV |
|---|---|---|
| Relative Strength Index (RSI) | 62.13 | 69.58 |
| Support Level | $13.46 | $21.55 |
| Resistance Level | $13.60 | $26.65 |
| Average True Range (ATR) | 0.05 | 0.93 |
| MACD | -0.03 | 0.23 |
| Stochastic Oscillator | 35.71 | 99.14 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.